News - 28 Mar 2012
Among patients with a high risk of recurrence of a gastrointestinal stromal tumor following surgery for its removal, patients who received imatinib (a drug to treat certain cancers) for 3 years...
News - 5 Jun 2006
Children with a rare digestive-tract cancer that is resistant to front-line therapy have benefited from a newer targeted therapy that has been shown effective in adults, according to data from a small...
News - 9 Jun 2004
A drug originally developed to block the formation of blood vessels in tumors has been shown to overcome resistance to treatment with Gleevec in patients with gastrointestinal stromal tumors (GIST).
News - 18 Aug 2017
Researchers at UC San Diego Moores Cancer Center, with colleagues from Memorial Sloan Kettering Cancer Center and Fox Chase Cancer Center, have determined that a specific region of the small bowel,...
News - 17 Feb 2017
Many who have a chronic traumatic brain injury (TBI) report struggling to solve problems, understand complex information and maintain friendships, despite scoring normally on cognitive tests.
News - 17 Aug 2016
GIST (Gastrointestinal Stromal Tumor) is an uncommon type of sarcoma found in the tissues supporting the digestive system (stomach and intestines).
News - 14 Jun 2016
New research from the Center for BrainHealth at The University of Texas at Dallas shows that strategy-based reasoning training can improve the cognitive performance for those with mild cognitive...
News - 11 Jun 2013
ARIAD Pharmaceuticals, Inc. today announced the initiation of the Phase 2 trial of Iclusig (ponatinib) in adult patients with metastatic and/or unresectable gastrointestinal stromal tumors.
News - 9 Apr 2013
A study presented at the AACR Annual Meeting 2013 indicates that a DNA blood test using Inostics' BEAMing Digital PCR can detect more mutations associated with secondary drug resistance in GIST...
News - 29 Nov 2012
Regorafenib is effective for patients with gastrointestinal stromal tumors who have failed to respond to treatment with imatinib and sunitinib, trial results show.